Compound 9j (anti-inflammatory agent 55), a Coixol derivative, exhibits anti-inflammatory properties by inhibiting the NF-κB pathway and reducing the expression of iNOS, TNF-α, IL-6, and IL-1β. It notably suppresses LPS-induced nitric oxide (NO) production in RAW264.7 macrophages with an IC50 of 0.8 μM and demonstrates anti-inflammatory effects in vivo using a mouse auricular edema model [1].